----item----
version: 1
id: {02561F83-6F66-47D4-B580-B90F81A1DB92}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/24/Albireo Appoints Ron Cooper CEO
parent: {D0AAADAC-3A4D-4719-8453-0B9B929C7097}
name: Albireo Appoints Ron Cooper CEO
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 896762de-bb2d-46f2-8cc5-202425ae120b

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 31

Albireo Appoints Ron Cooper CEO
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 31

Albireo Appoints Ron Cooper CEO
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 909

<p>Albireo Limited, a privately held company focused on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH, and gastrointestinal disorders, has named Ron Cooper president and CEO. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the US and Europe. He joins Albireo from Bristol-Myers Squibb (BMS), where he was president of Europe. During his more than 25 years at BMS, Cooper worked in five different countries and held positions of increasing responsibility in sales, marketing and general management.</p><p>In addition, Albireo, which was spun out of AstraZeneca in 2008, has established a US subsidiary office in Boston, Massachusetts. Albireo Limited is incorporated and registered in England and Wales, and its wholly owned subsidiaries are located in Gothenburg, Sweden and now Boston. </p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 619

<p>Albireo Limited, a privately held company focused on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH, and gastrointestinal disorders, has named Ron Cooper president and CEO. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the US and Europe. He joins Albireo from Bristol-Myers Squibb (BMS), where he was president of Europe. During his more than 25 years at BMS, Cooper worked in five different countries and held positions of increasing responsibility in sales, marketing and general management.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 31

Albireo Appoints Ron Cooper CEO
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150924T180003
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150924T180003
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150924T180003
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029865
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 31

Albireo Appoints Ron Cooper CEO
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360579
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042455Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

896762de-bb2d-46f2-8cc5-202425ae120b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042455Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
